Predicted Atherosclerotic Cardiovascular Disease Risk and Masked Hypertension Among Blacks in the Jackson Heart Study

D Edmund Anstey1, John N Booth2, Marwah Abdalla2

  • 1From the Department of Medicine, Columbia University Medical Center, New York, NY (D.E.A., M.A., D.S.); Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL (J.N.B., P.M.); Department of Population Health, New York University School of Medicine, New York, NY (T.M.S.); and School of Medicine, University of Mississippi Medical Center, Jackson, MS (Y.-I.M.). dea2123@cumc.columbia.edu.

Insights

Individuals with higher predicted atherosclerotic cardiovascular disease (ASCVD) risk face a greater likelihood of masked hypertension. This finding suggests using ASCVD risk scores to identify those needing further blood pressure screening.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Preventive Medicine

Background:

  • Masked hypertension, undiagnosed hypertension outside clinical settings, poses a risk.
  • Identifying individuals for masked hypertension screening is challenging.
  • This study investigates the link between predicted atherosclerotic cardiovascular disease (ASCVD) risk and masked hypertension prevalence.

Purpose of the Study:

  • To determine if higher 10-year predicted ASCVD risk is associated with a greater prevalence of masked hypertension.
  • To assess the utility of ASCVD risk prediction in identifying individuals with masked hypertension.

Main Methods:

  • Analysis of data from the Jackson Heart Study, a population-based cohort of Black individuals.
  • Inclusion of 644 participants aged 40-79 without diagnosed hypertension or cardiovascular disease.
  • Calculation of 10-year predicted ASCVD risk using pooled cohort equations and ambulatory blood pressure monitoring for masked hypertension diagnosis.

Main Results:

  • The prevalence of any masked hypertension was 54.0% in the study population.
  • Individuals in higher ASCVD risk categories (≥7.5%) showed significantly increased prevalence ratios for masked hypertension compared to the lowest risk group (<5%).
  • ASCVD risk prediction showed moderate discrimination for masked hypertension, comparable to clinic blood pressure measurements.

Conclusions:

  • Elevated ASCVD risk is linked to a higher prevalence of masked hypertension.
  • While not superior to clinic BP for discrimination, ASCVD risk prediction may aid in identifying individuals with both masked hypertension and high ASCVD risk.
  • Further research may refine risk prediction models for targeted screening of masked hypertension.
Abstract

Related Concept Videos

Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.2K
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
679
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
512
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.3K
Hypertension I: Introduction01:28

Hypertension I: Introduction

Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
1.0K
Bias in Epidemiological Studies01:29

Bias in Epidemiological Studies

Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:  
1.4K